Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): A randomised, phase 3, open-label, 2×2 factorial trial

The Lancet Oncology

Volumn 14, Issue 6, 2013, Pages 516-524

  James, Roger D ^a   Glynne Jones, Robert ^b   Meadows, Helen M ^c   Cunningham, David ^d   Myint, Arthur Sun ^e   Saunders, Mark P ^f   Maughan, Timothy ^g   McDonald, Alec ^h   Essapen, Sharadah ⁱ   Leslie, Martin ^j   Falk, Stephen ^k   Wilson, Charles ^l   Gollins, Simon ^m   Begum, Rubina ^c   Ledermann, Jonathan ^c   Kadalayil, Latha ^c   Sebag Montefiore, David ⁿ  

^a Kent Cancer Centre   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^f CHRISTIE HOSPITAL   (United Kingdom)

^g VELINDRE CANCER CENTRE   (United Kingdom)

^h BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

ⁱ ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^j ST THOMAS HOSPITAL   (United Kingdom)

^k BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^l ADDENBROOKE S HOSPITAL   (United Kingdom)

^m GLAN CLWYD HOSPITAL   (United Kingdom)

ⁿ UNIVERSITY OF LEEDS   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; MITOMYCIN;

ACUTE TOXICITY; ADULT; AGE; AGED; ANUS CANCER; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CHEMORADIOTHERAPY; COLOSTOMY FREE SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; HEART DISEASE; HUMAN; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEX; SINGLE DRUG DOSE; SKIN TOXICITY; STOMATITIS; SURVIVAL; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR LOCALIZATION; UNITED KINGDOM; UROGENITAL TRACT DISEASE; VASCULAR DISEASE; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; GREAT BRITAIN; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84876995829     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70086-X     Document Type: Article

References (25)

1. Brewster DH, Bhatti LA Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975-2002. Br J Cancer 2006, 5:87-90.
2. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum 2009, 52:624-631.
3. Epidermoid Anal Cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil and mitomycin. Lancet 1996, 348:1049-1054. UKCCCR Anal Cancer Working Party.
4. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997, 15:2040-2049.
5. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996, 14:2527-2539.
6. Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 2010, 102:1123-1128.
7. Rich TA, Ajani JA, Morrison WH, Ota D, Levin B Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin. Radiother Oncol 1993, 27:209-215.
8. Doci R, Zucali R, La Monica G, et al. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. J Clin Oncol 1996, 14:3121-3125.
9. Gerard JP, Ayzac L, Hun D, et al. Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients. Radiother Oncol 1998, 46:249-256.
10. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin and radiotherapy vs fluorouracil, cisplatin and radiotherapy for carcinoma of the anal canal: a randomised controlled trial. JAMA 2008, 199:1914-1921.
11. Peiffert D, Tournier-Rangeard L, Gérard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 2012, 30:1941-1948.
12. Sebag-Montefiore D, Meadows HM, Cunningham D, et al. Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluoruracil, mitomycin c and cisplatin. Radiother Oncol 2012, 104:155-160.
13. ICRU report 50, precribing, recording and reporting photon beam therapy 1993, International Commission on Radiation Units and Measurements, Bethesda.
14. Union Internationale Contre Le Cancer (UICC) TNM-Atlas, Illustrated guide to the TNM/pTNM-classification of malignant tumours 1990, Springer-Verlag, Berlin, Heidelberg. 4th edn. B. Spiessl, P. Hermanek, O. Scheibe, G. Wagner (Eds.).
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
16. Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of U.S. GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluoruracil/cisplatin. J Clin Oncol 2012, 30:4344-4351.
17. National Comprehensive Cancer Network (NCCN) clinical guidelines in oncology. Anal carcinoma, version 2.2013. National Comprehensive Cancer Network NCCN, (accessed March 26, 2013). http://www.nccn.org/professionals/physician_gls/pdf/anal.pdf.
18. Konski A, Garcia M, John M, et al. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys 2008, 72:114-118.
19. Glynne-Jones R, Sebag-Montefiore D, Adams R, et al. " Mind the gap" -the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I). Int J Radiat Oncol Biol Phys 2011, 81:1488-1494.
20. Kachnic L, Winter K, Myerson R, et al. RTOG 0529: a phase II evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2012, published online Nov 12. 10.1016/j.ijrobp.2012.09.023.
21. Weber DC, Kurtz J, Allal AS Impact duration of local control in anal canal carcinoma treated by split course radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys 2001, 50:675-680.
22. Graf R, Wust P, Hilderbrant B, et al. Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy. Oncology 2003, 65:14-22.
23. Chakravarthy AB, Catalano PJ, Martenson JA, et al. Long-term follow-up of a phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292). Int J Radiat Oncol Biol Phys 2011, 81:e607-e613.
24. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007, 357:1705-1715. TAX 324 Study Group.
25. Garg M, Lee JY, Kachnic LA, et al. Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): safety and preliminary efficacy results. Proc Am Soc Clin Oncol 2012, 30(suppl). abstr 4030.